Thomas Andrew Rowland Sells 459 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Thomas Andrew Rowland sold 459 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $79.21, for a total transaction of $36,357.39. Following the completion of the sale, the senior vice president owned 38,271 shares in the company, valued at $3,031,445.91. The trade was a 1.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Thomas Andrew Rowland also recently made the following trade(s):

• On Wednesday, March 11th, Thomas Andrew Rowland sold 4,772 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $74.91, for a total transaction of $357,470.52.

ANI Pharmaceuticals Stock Down 1.6%

Shares of ANIP stock opened at $79.58 on Friday. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06. ANI Pharmaceuticals, Inc. has a 1 year low of $56.71 and a 1 year high of $99.50. The firm’s fifty day moving average price is $77.26 and its two-hundred day moving average price is $80.50. The firm has a market capitalization of $1.78 billion, a P/E ratio of 20.15 and a beta of 0.46.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. During the same period in the previous year, the business earned $1.70 EPS. The company’s revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities analysts predict that ANI Pharmaceuticals, Inc. will post 7.73 EPS for the current fiscal year.

Trending Headlines about ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI Pharmaceuticals posted a strong first quarter, with EPS of $2.05 beating estimates of $1.28 and revenue of $237.46 million topping expectations, while management also guided FY2026 EPS to $9.19-$9.69, reinforcing the company’s growth story.
• Positive Sentiment: Analyst sentiment remains favorable, with recent upgrades and a consensus “Moderate Buy” rating plus an average price target above the current trading range, which can support longer-term confidence in ANIP.
• Neutral Sentiment: ANI Pharmaceuticals updated its investor presentation and highlighted non-GAAP metrics, a routine corporate communication that does not appear to materially change the near-term outlook. ANI Pharmaceuticals Updates Investor Presentation, Highlights Non-GAAP Metrics
• Negative Sentiment: CEO Nikhil Lalwani sold 55,000 shares, and other executives and directors also trimmed holdings, including Patrick D. Walsh, Meredith Cook, Ori Gutwerg, and Thomas Andrew Rowland; heavy insider selling can weigh on sentiment even when some trades are pre-planned.
• Negative Sentiment: A separate filing reported that Global Alpha sold 229,000 ANIP shares worth about $17.9 million, adding to concerns that a large investor may be reducing exposure. Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 15th. Finally, Guggenheim lifted their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a report on Friday, January 16th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $107.33.

Institutional Trading of ANI Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Hantz Financial Services Inc. boosted its holdings in shares of ANI Pharmaceuticals by 202.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after buying an additional 237 shares during the period. KBC Group NV bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth about $28,000. Advisors Asset Management Inc. bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth about $28,000. Kemnay Advisory Services Inc. bought a new stake in ANI Pharmaceuticals in the 4th quarter valued at about $48,000. Finally, State of Wyoming bought a new stake in ANI Pharmaceuticals in the 2nd quarter valued at about $50,000. Institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.